Finberg JP, Gillman K (2011). "Selective inhibitors of monoamine oxidase type B and the "cheese effect"". Monoamine Oxidase and their Inhibitors. International Review of Neurobiology. Vol. 100. pp. 169–190. doi:10.1016/B978-0-12-386467-3.00009-1. ISBN978-0-12-386467-3. PMID21971008.
Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. (January 2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin". Synapse. 39 (1): 32–41. doi:10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3. PMID11071707.
Xie Z, Westmoreland SV, Miller GM (May 2008). "Modulation of monoamine transporters by common biogenic amines via trace amine-associated receptor 1 and monoamine autoreceptors in human embryonic kidney 293 cells and brain synaptosomes". The Journal of Pharmacology and Experimental Therapeutics. 325 (2): 629–640. doi:10.1124/jpet.107.135079. PMID18310473. S2CID178180.
Khan MZ, Nawaz W (October 2016). "The emerging roles of human trace amines and human trace amine-associated receptors (hTAARs) in central nervous system". Biomedicine & Pharmacotherapy. 83: 439–449. doi:10.1016/j.biopha.2016.07.002. PMID27424325.
Lindemann L, Hoener MC (May 2005). "A renaissance in trace amines inspired by a novel GPCR family". Trends in Pharmacological Sciences. 26 (5): 274–281. doi:10.1016/j.tips.2005.03.007. PMID15860375.
Wang X, Li J, Dong G, Yue J (February 2014). "The endogenous substrates of brain CYP2D". European Journal of Pharmacology. 724: 211–218. doi:10.1016/j.ejphar.2013.12.025. PMID24374199.
Stahl SM, Felker A (October 2008). "Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants". CNS Spectrums. 13 (10): 855–870. doi:10.1017/S1092852900016965. PMID18955941. S2CID6118722.
D'Andrea G, Nordera GP, Perini F, Allais G, Granella F (May 2007). "Biochemistry of neuromodulation in primary headaches: focus on anomalies of tyrosine metabolism". Neurological Sciences. 28 (S2): S94-6. doi:10.1007/s10072-007-0758-4. PMID17508188. S2CID1548732.
McCabe BJ (August 1986). "Dietary tyramine and other pressor amines in MAOI regimens: a review". Journal of the American Dietetic Association. 86 (8): 1059–64. doi:10.1016/S0002-8223(21)04074-8. PMID3525654. S2CID902921.
Shimazu S, Miklya I (May 2004). "Pharmacological studies with endogenous enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic derivatives". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 28 (3): 421–427. doi:10.1016/j.pnpbp.2003.11.016. PMID15093948. S2CID37564231.
Knoll J (August 2003). "Enhancer regulation/endogenous and synthetic enhancer compounds: a neurochemical concept of the innate and acquired drives". Neurochem Res. 28 (8): 1275–1297. doi:10.1023/a:1024224311289. PMID12834268.
Knoll J, Miklya I, Knoll B, Markó R, Rácz D (1996). "Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brain". Life Sci. 58 (23): 2101–2114. doi:10.1016/0024-3205(96)00204-4. PMID8649195.
Waser E (1925). "Untersuchungen in der Phenylalanin-Reihe VI. Decarboxylierung des Tyrosins und des Leucins". Helvetica Chimica Acta. 8: 758–773. doi:10.1002/hlca.192500801106.
Buck JS (1933). "Reduction of Hydroxymandelonitriles. A New Synthesis of Tyramine". Journal of the American Chemical Society. 55 (8): 3388–3390. doi:10.1021/ja01335a058.
Finberg JP, Gillman K (2011). "Selective inhibitors of monoamine oxidase type B and the "cheese effect"". Monoamine Oxidase and their Inhibitors. International Review of Neurobiology. Vol. 100. pp. 169–190. doi:10.1016/B978-0-12-386467-3.00009-1. ISBN978-0-12-386467-3. PMID21971008.
Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. (January 2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin". Synapse. 39 (1): 32–41. doi:10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3. PMID11071707.
Philips SR, Rozdilsky B, Boulton AA (February 1978). "Evidence for the presence of m-tyramine, p-tyramine, tryptamine, and phenylethylamine in the rat brain and several areas of the human brain". Biological Psychiatry. 13 (1): 51–7. PMID623853.
Xie Z, Westmoreland SV, Miller GM (May 2008). "Modulation of monoamine transporters by common biogenic amines via trace amine-associated receptor 1 and monoamine autoreceptors in human embryonic kidney 293 cells and brain synaptosomes". The Journal of Pharmacology and Experimental Therapeutics. 325 (2): 629–640. doi:10.1124/jpet.107.135079. PMID18310473. S2CID178180.
Khan MZ, Nawaz W (October 2016). "The emerging roles of human trace amines and human trace amine-associated receptors (hTAARs) in central nervous system". Biomedicine & Pharmacotherapy. 83: 439–449. doi:10.1016/j.biopha.2016.07.002. PMID27424325.
Lindemann L, Hoener MC (May 2005). "A renaissance in trace amines inspired by a novel GPCR family". Trends in Pharmacological Sciences. 26 (5): 274–281. doi:10.1016/j.tips.2005.03.007. PMID15860375.
Wang X, Li J, Dong G, Yue J (February 2014). "The endogenous substrates of brain CYP2D". European Journal of Pharmacology. 724: 211–218. doi:10.1016/j.ejphar.2013.12.025. PMID24374199.
Stahl SM, Felker A (October 2008). "Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants". CNS Spectrums. 13 (10): 855–870. doi:10.1017/S1092852900016965. PMID18955941. S2CID6118722.
D'Andrea G, Nordera GP, Perini F, Allais G, Granella F (May 2007). "Biochemistry of neuromodulation in primary headaches: focus on anomalies of tyrosine metabolism". Neurological Sciences. 28 (S2): S94-6. doi:10.1007/s10072-007-0758-4. PMID17508188. S2CID1548732.
McCabe BJ (August 1986). "Dietary tyramine and other pressor amines in MAOI regimens: a review". Journal of the American Dietetic Association. 86 (8): 1059–64. doi:10.1016/S0002-8223(21)04074-8. PMID3525654. S2CID902921.
Shimazu S, Miklya I (May 2004). "Pharmacological studies with endogenous enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic derivatives". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 28 (3): 421–427. doi:10.1016/j.pnpbp.2003.11.016. PMID15093948. S2CID37564231.
Knoll J (August 2003). "Enhancer regulation/endogenous and synthetic enhancer compounds: a neurochemical concept of the innate and acquired drives". Neurochem Res. 28 (8): 1275–1297. doi:10.1023/a:1024224311289. PMID12834268.
Knoll J, Miklya I, Knoll B, Markó R, Rácz D (1996). "Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brain". Life Sci. 58 (23): 2101–2114. doi:10.1016/0024-3205(96)00204-4. PMID8649195.
Xie Z, Westmoreland SV, Miller GM (May 2008). "Modulation of monoamine transporters by common biogenic amines via trace amine-associated receptor 1 and monoamine autoreceptors in human embryonic kidney 293 cells and brain synaptosomes". The Journal of Pharmacology and Experimental Therapeutics. 325 (2): 629–640. doi:10.1124/jpet.107.135079. PMID18310473. S2CID178180.
Stahl SM, Felker A (October 2008). "Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants". CNS Spectrums. 13 (10): 855–870. doi:10.1017/S1092852900016965. PMID18955941. S2CID6118722.
D'Andrea G, Nordera GP, Perini F, Allais G, Granella F (May 2007). "Biochemistry of neuromodulation in primary headaches: focus on anomalies of tyrosine metabolism". Neurological Sciences. 28 (S2): S94-6. doi:10.1007/s10072-007-0758-4. PMID17508188. S2CID1548732.
McCabe BJ (August 1986). "Dietary tyramine and other pressor amines in MAOI regimens: a review". Journal of the American Dietetic Association. 86 (8): 1059–64. doi:10.1016/S0002-8223(21)04074-8. PMID3525654. S2CID902921.
Shimazu S, Miklya I (May 2004). "Pharmacological studies with endogenous enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic derivatives". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 28 (3): 421–427. doi:10.1016/j.pnpbp.2003.11.016. PMID15093948. S2CID37564231.